Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed or Refractory Multiple Myeloma (RRMM)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT05064358
What this trial is testing

Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
GlaxoSmithKline 177
Large-scale testing (Phase 3)Ended earlyNCT02576977
What this trial is testing

Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183)

Who this might be right for
Multiple Myeloma
Merck Sharp & Dohme LLC 251
Testing effectiveness (Phase 2)Looking for participantsNCT04643002
What this trial is testing

Isatuximab in Combination With Novel Agents in RRMM - Master Protocol

Who this might be right for
Plasma Cell Myeloma Refractory
Sanofi 258
Testing effectiveness (Phase 2)Looking for participantsNCT07266441
What this trial is testing

JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Janssen Research & Development, LLC 157
Testing effectiveness (Phase 2)Study completedNCT02461888
What this trial is testing

Phase II Randomised Trial of Cyclophosphamide & Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma.

Who this might be right for
Multiple Myeloma
University of Leeds 112
Large-scale testing (Phase 3)WithdrawnNCT06232707
What this trial is testing

Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Who this might be right for
Multiple Myeloma
Celgene
Testing effectiveness (Phase 2)Looking for participantsNCT06484829
What this trial is testing

Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma (RRMM)
Chengdu Zenitar Biomedical Technology Co., Ltd 144
Testing effectiveness (Phase 2)Study completedNCT03439293
What this trial is testing

Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)

Who this might be right for
Multiple Myeloma
Takeda 61
Early research (Phase 1)WithdrawnNCT04392648
What this trial is testing

Evaluate the Safety, Tolerability and Efficacy of Intravenous TAK-573 as Part of Combination Therapy in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Who this might be right for
Relapsed and/or Refractory Multiple Myeloma
Teva Branded Pharmaceutical Products R&D LLC
Not applicableStudy completedNCT05887206
What this trial is testing

Corneal Toxicity in Patients Treated by Belantamab Mafodotin

Who this might be right for
Myeloma Multiple
Centre Hospitalier Universitaire de Saint Etienne 43
Testing effectiveness (Phase 2)Study completedNCT02045017
What this trial is testing

Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency

Who this might be right for
Multiple Myeloma
Celgene 81
Testing effectiveness (Phase 2)Looking for participantsNCT07637578
What this trial is testing

Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma (MM)Multiple Myeloma RefractoryMultiple Myeloma in Relapse+1 more
SCRI Development Innovations, LLC 46
Not applicableActive Not RecruitingNCT07391761
What this trial is testing

A Real World Study of Elranatamab in Patients With RR Multiple Myeloma in Taiwan

Who this might be right for
Refractory Multiple Myeloma (RRMM)
Pfizer 1
Testing effectiveness (Phase 2)WithdrawnNCT06352866
What this trial is testing

Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM

Who this might be right for
Multiple MyelomaCytokine Release SyndromeRefractory Multiple Myeloma+1 more
Jack Khouri, MD
Early research (Phase 1)Active Not RecruitingNCT04398745
What this trial is testing

Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function

Who this might be right for
Multiple Myeloma
GlaxoSmithKline 36
Large-scale testing (Phase 3)Ended earlyNCT03151811
What this trial is testing

Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide

Who this might be right for
Multiple Myeloma
Oncopeptides AB 495
Early research (Phase 1)Looking for participantsNCT07003568
What this trial is testing

Dual-target BCMA-GPRC5D CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration

Who this might be right for
Relapsed or Refractory Multiple Myeloma (RRMM)
Beijing GoBroad Hospital 18
Early research (Phase 1)Active Not RecruitingNCT05675449
What this trial is testing

A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Pfizer 59
Early research (Phase 1)Ended earlyNCT04272775
What this trial is testing

MLN9708 in Japanese Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)

Who this might be right for
Relapsed and/or Refractory Multiple Myeloma
Takeda 14
Early research (Phase 1)Ended earlyNCT03582033
What this trial is testing

A Safety Study of SEA-BCMA in Patients With Multiple Myeloma

Who this might be right for
Multiple Myeloma
Seagen Inc. 83
Next Page